Eupraxia Pharmaceuticals (EPRX) Q2 2025 earnings summary

Executive summary

• Dosed first patient in Phase 2b placebo-controlled RESOLVE trial for EP-104GI in EoE, with topline data expected in H2 2026.

• Positive nine-month data from Phase 1b/2a RESOLVE trial showed sustained treatment outcomes and no serious adverse events.

• Additional data from Phase 1b/2a cohorts 5-8 expected in October 2025.

Financial highlights

• Net loss of $8.7 million for Q2 2025, compared to $6.1 million in Q2 2024, driven by higher R&D and administrative costs.

• Cash balance of $19.8 million as of June 30, 2025, down from $33.1 million at year-end 2024.

• 35,959,568 common shares and 8,905,638 preferred shares outstanding as of June 30, 2025.

Outlook and guidance

• Existing cash and anticipated warrant proceeds expected to fund operations into Q3 2026.

• Topline Phase 2b RESOLVE trial data anticipated in H2 2026; additional Phase 1b/2a data in October 2025.